TY - JOUR
T1 - Tumour-targeting bacteria engineered to fight cancer
AU - Zhou, Shibin
AU - Gravekamp, Claudia
AU - Bermudes, David
AU - Liu, Ke
N1 - Funding Information:
This work was supported by The Virginia and D.K. Ludwig Fund for Cancer Research (S.Z.), BioMed Valley Discoveries, Inc. (S.Z.), Pancreatic Cancer Action Network grant PCAN-422247 (C.G.) and US National Institutes of Health (NIH) grants CA062924 (S.Z.), CA199010 (C.G.) and GM098207 (D.B.).
Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.
AB - Recent advances in targeted therapy and immunotherapy have once again raised the hope that a cure might be within reach for many cancer types. Yet, most late-stage cancers are either insensitive to the therapies to begin with or develop resistance later. Therapy with live tumour-targeting bacteria provides a unique option to meet these challenges. Compared with most other therapeutics, the effectiveness of tumour-targeting bacteria is not directly affected by the ‘genetic makeup’ of a tumour. Bacteria initiate their direct antitumour effects from deep within the tumour, followed by innate and adaptive antitumour immune responses. As microscopic ‘robotic factories’, bacterial vectors can be reprogrammed following simple genetic rules or sophisticated synthetic bioengineering principles to produce and deliver anticancer agents on the basis of clinical needs. Therapeutic approaches using live tumour-targeting bacteria can either be applied as a monotherapy or complement other anticancer therapies to achieve better clinical outcomes. In this Review, we summarize the potential benefits and challenges of this approach. We discuss how live bacteria selectively induce tumour regression and provide examples to illustrate different ways to engineer bacteria for improved safety and efficacy. Finally, we share our experience and insights on oncology clinical trials with tumour-targeting bacteria, including a discussion of the regulatory issues.
UR - http://www.scopus.com/inward/record.url?scp=85056343066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056343066&partnerID=8YFLogxK
U2 - 10.1038/s41568-018-0070-z
DO - 10.1038/s41568-018-0070-z
M3 - Review article
C2 - 30405213
AN - SCOPUS:85056343066
SN - 1474-175X
VL - 18
SP - 727
EP - 743
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 12
ER -